Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 16/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484649 | 0.91 | GRIA2 (0.51) | GRIA2PGR | |
| SCHEMBL5482709 | 0.89 | LTA4H (0.41) | GRIA2LTA4HPGRMMP2MMP3 | |
| SCHEMBL5479962 | 0.86 | GRIA2 (0.52) | GRIA2 | |
| SCHEMBL5475951 | 0.83 | GRIA2 (0.68) | GRIA2MMP2MMP9 | |
| SCHEMBL5477044 | 0.82 | GRIA2 (0.49) | GRIA2 | |
| SCHEMBL5482325 | 0.82 | GRIA2 (0.51) | GRIA2 | |
| SCHEMBL5484644 | 0.81 | GRIA2 (0.40) | GRIA2PGR | |
| SCHEMBL5481775 | 0.80 | GRIA2 (0.49) | GRIA2 | |
| SCHEMBL5621042 | 0.80 | GRIA2 (0.53) | GRIA2PGR | |
| SCHEMBL2178739 | 0.80 | GRIA2 (0.71) | GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655030-B1 | Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same | SERVIER LAB (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20070270415-A1 | Benzothiadiazine compounds | LESLABORATOIRES SERVIER (FR) | 2007-11-22 | — | — | US | disclosed |
| US-7268130-B2 | Benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2007-09-11 | — | — | US | disclosed |
| EP-1655030-A1 | Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same | Les Laboratoires Servier (FR) | 2006-05-10 | — | — | EP | disclosed |
| US-20060094712-A1 | New benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270415-A1 | Benzothiadiazine compounds | SLC1A1, SLC1A2, SULT2A1 | GRIA2 47/4885LTA4H 2272/4885PGR 2853/4885 |
| US-20060094712-A1 | New benzothiadiazine compounds | SLC1A1, SLC1A2, GABRA5 | GRIA2 36/4885LTA4H 1985/4885PGR 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.